IL309813A - ANTISENSE OLIGONUCLEOTIDE (ASO) gene inhibition and treatment - Google Patents

ANTISENSE OLIGONUCLEOTIDE (ASO) gene inhibition and treatment

Info

Publication number
IL309813A
IL309813A IL309813A IL30981323A IL309813A IL 309813 A IL309813 A IL 309813A IL 309813 A IL309813 A IL 309813A IL 30981323 A IL30981323 A IL 30981323A IL 309813 A IL309813 A IL 309813A
Authority
IL
Israel
Prior art keywords
aso
treatment
antisense oligonucleotide
gene inhibition
inhibition
Prior art date
Application number
IL309813A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of IL309813A publication Critical patent/IL309813A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/34Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL309813A 2021-07-15 2022-07-13 ANTISENSE OLIGONUCLEOTIDE (ASO) gene inhibition and treatment IL309813A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222336P 2021-07-15 2021-07-15
US202163224362P 2021-07-21 2021-07-21
PCT/US2022/073668 WO2023288240A1 (en) 2021-07-15 2022-07-13 Antisense oligonucleotide (aso) gene inhibition and treatment

Publications (1)

Publication Number Publication Date
IL309813A true IL309813A (en) 2024-02-01

Family

ID=82850241

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309813A IL309813A (en) 2021-07-15 2022-07-13 ANTISENSE OLIGONUCLEOTIDE (ASO) gene inhibition and treatment

Country Status (8)

Country Link
EP (1) EP4370133A1 (https=)
JP (1) JP2024525837A (https=)
KR (1) KR20240037996A (https=)
AU (1) AU2022312494A1 (https=)
CA (1) CA3224471A1 (https=)
IL (1) IL309813A (https=)
MX (1) MX2024000636A (https=)
WO (1) WO2023288240A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121039279A (zh) * 2023-05-05 2025-11-28 万达制药公司 反义寡核苷酸(aso)基因抑制和治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161046A1 (en) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Methods of treating diseases characterized by excessive wnt signalling
WO2017214463A1 (en) * 2016-06-09 2017-12-14 The Regents Of The University Of California Compositions and methods for treating cancer and biomarkers to detect cancer stem cell reprogramming and progression

Also Published As

Publication number Publication date
AU2022312494A9 (en) 2024-01-25
MX2024000636A (es) 2024-02-06
WO2023288240A8 (en) 2023-12-14
AU2022312494A1 (en) 2024-01-18
JP2024525837A (ja) 2024-07-12
EP4370133A1 (en) 2024-05-22
KR20240037996A (ko) 2024-03-22
CA3224471A1 (en) 2023-01-19
WO2023288240A1 (en) 2023-01-19
WO2023288240A9 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
IL274023A (en) Antisense oligomers for the treatment of condition- and disease-based nonsense-mediated RNA decay
WO2009017803A3 (en) Antisense microrna and uses therefor
IL288574A (en) Oligonucleotides and methods for use in the treatment of neurological diseases
MX2023015242A (es) Tratamiento de enfermedades y trastornos relacionados con mtres1.
IL279692A (en) A preparation containing antisense oligonucleotides and their uses for the treatment of Duchenne syndrome
IL285867A (en) Antisense oligomers for the treatment of conditions and diseases
IL309813A (en) ANTISENSE OLIGONUCLEOTIDE (ASO) gene inhibition and treatment
EP3384028A4 (en) MONOCARBOXYLATE TRANSPORTER 4 (MCT4) ANTISENSE OLIGONUCLEOTIDE (ASO) INHIBITORS FOR USE AS THERAPEUTICS IN THE TREATMENT OF CANCER
IL307787A (en) ANTISENSE OLIGONUCLEOTIDES and their use for the treatment of neurodegenerative disorders
IL309445A (en) PIKFYVE antisense oligonucleotides
HK1245826A1 (zh) 用於治疗营养不良性大疱性表皮松解症的反义寡核苷酸
CA3287784A1 (en) Antisense oligonucleotide (aso) gene inhibition and treatment
WO2008038267A3 (en) Use of antisense oligonucleotides against cpla2 in the treatment of cancer
MX2025011513A (es) Oligonucleotidos antisentido (aso) inhibidores de smad7 para el tratamiento de la pouchitis y metodos de uso de los mismos
IL306119A (en) Gene therapy for the treatment of beta-hemoglobinopathies
EP4428236A4 (en) ANTISENSE OLIGONUCLEOTIDES
CA3271562A1 (en) Antisense oligonucleotides for treatment of usher 2a. exons 39-40
CA3285154A1 (en) Smad7 inhibitory antisense oligonucleotides (aso) for treating pouchitis and methods of using the same
GB202215198D0 (en) Gene therapy treatment
GB202502460D0 (en) Antisense oligonucleotides for the treatment of cancer
GB202319556D0 (en) Antisense oligonculeotides for the treatment of charcot-marie-tooth type 1A disease
GB202005321D0 (en) Gene therapy treatment
AU2023470083A1 (en) Antisense oligonucleotides and medical use thereof
CA3307096A1 (en) Antisense oligonucleotides and medical use thereof